Current status of hepatitis C virus infection and countermeasures in South Korea
2
조회
0
다운로드
19
인용
0
참고문헌
키워드
초록
Hepatitis C virus (HCV) infection is a major cause of liver cirrhosis, hepatocellular carcinoma, and liver-related mortality. The new antiviral drugs against HCV, direct acting antivirals, result in >90% cure rate. This review aimed to summarize the current prevalence, clinical characteristics, outcomes, and treatment response associated with HCV infection, and countermeasures for optimal HCV control in South Korea. Based on a literature review, the current anti-HCV prevalence in the Korean population is 0.6 to 0.8%, with increasing prevalence according to age. The major HCV genotypes in Korean patients were genotype 1b and genotype 2. Successful antiviral treatment leads to significantly reduced liver related complications and mortality. However, only about one third of the individuals with HCV infection seem to be managed under the current national health insurance system, suggesting a remarkable rate of underdiagnoses and subsequent loss of opportunity to cure. A recent study in South Korea showed that targeted population screening for HCV infection is cost-effective. To prevent recently developed clusters of HCV infection in some clinics, mandatory surveillance rather than sentinel surveillance for HCV infection is required and governmental countermeasures to prevent reuse of syringes or other medical devises, and public education should be maintained. Moreover, one-time screening for a targeted population should be considered and a cost-effectiveness study supporting an optimal screening strategy is warranted.
Abstract
Hepatitis C virus (HCV) infection is a major cause of liver cirrhosis, hepatocellular carcinoma, and liver-related mortality. The new antiviral drugs against HCV, direct acting antivirals, result in >90% cure rate. This review aimed to summarize the current prevalence, clinical characteristics, outcomes, and treatment response associated with HCV infection, and countermeasures for optimal HCV control in South Korea. Based on a literature review, the current anti-HCV prevalence in the Korean population is 0.6 to 0.8%, with increasing prevalence according to age. The major HCV genotypes in Korean patients were genotype 1b and genotype 2. Successful antiviral treatment leads to significantly reduced liver related complications and mortality. However, only about one third of the individuals with HCV infection seem to be managed under the current national health insurance system, suggesting a remarkable rate of underdiagnoses and subsequent loss of opportunity to cure. A recent study in South Korea showed that targeted population screening for HCV infection is cost-effective. To prevent recently developed clusters of HCV infection in some clinics, mandatory surveillance rather than sentinel surveillance for HCV infection is required and governmental countermeasures to prevent reuse of syringes or other medical devises, and public education should be maintained. Moreover, one-time screening for a targeted population should be considered and a cost-effectiveness study supporting an optimal screening strategy is warranted.
참고문헌 (12)
- Kim DY, "A nationwide seroepidemiology of hepatitis C virus infection in South Korea", Liver Int, 33, pp.586~594 (2013)
- 손혜석, "Comparison and analysis of the prevalence of hepatitis C virus infection by region in the Republic of Korea during 2005–2012", Clinical and Molecular Hepatology, 21(3), pp.249~256 (2015), 대한간학회
- Seong MH, "Clinical and epidemiological features of hepatitis C virus infection in South Korea: a prospective, multicenter cohort study", J Med Virol, 85, pp.1724~1733 (2013)
- Hae-Sook Sohn, "Risk Factors for Hepatitis C Virus (HCV) Infection in Areas with a High Prevalence of HCV in the Republic of Korea in 2013", Gut and Liver, 10(1), pp.126~132 (2016), 거트앤리버 발행위원회
- Ok KS, "The clinical outcomes of chronic hepatitis C in South Korea: a prospective, multicenter cohort study", Medicine (Baltimore), 95, pp.e4594~ (2016)
- Lee SS, "Prospective cohort study on the outcomes of hepatitis C virus-related cirrhosis in South Korea", J Gastroenterol Hepatol, 30, pp.1281~1287 (2015)
- 박상훈, "Efficacy and Tolerability of Peginterferon Alpha Plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Korea: A Multi-Center, Retrospective Observational Study", Gut and Liver, 6(1), pp.98~106 (2012), 거트앤리버 발행위원회
- 장은선, "Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era", Gut and Liver, 11(4), pp.543~550 (2017), 거트앤리버 발행위원회[DOI]
- Korean Association for the Study of the Liver, "KASL clinical practice guidelines: management of hepatitis C", Clin Mol Hepatol, 22, pp.76~139 (2016)
- Korea Centers for Diseases Control and Prevention, "Year book 2015: national infectious diseases surveillance, Korea", pp.531~532 (2016), Korea Centers for Diseases Control and Prevention
- Kim DY, "Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea", Medicine (Baltimore), 95, pp.e3896~ (2016)
- Kim DY, "Estimating the cost-effectiveness of one-time screening and treatment for hepatitis C in Korea", PLoS One, 12, pp.e0167770~ (2017)